Urokinase receptor mediates osteoclastogenesis via M-CSF release from osteoblasts and the c-Fms/PI3K/Akt/NF-κB pathway in osteoclasts

Journal of Bone and Mineral Research

Volumn 30, Issue 2, 2015, Pages 379-388

  Anaraki, Parnian Kalbasi ^a   Patecki, Margret ^a   Tkachuk, Sergey ^a   Kiyan, Yulia ^a   Haller, Hermann ^a   Dumler, Inna ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Bone modeling and cytokines; Cell tissue signaling; Endocrine pathways; Molecular pathways; Osteoblasts; Osteoclasts; Remodeling; Stromal stem cells

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CATHEPSIN K; COLONY STIMULATING FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; UROKINASE RECEPTOR; VASCULOTROPIN RECEPTOR 1; COLONY STIMULATING FACTOR RECEPTOR; UROKINASE;

APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL PROLIFERATION; CELL SURVIVAL; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOSKELETON; ENZYME ACTIVATION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; INTRACELLULAR SIGNALING; MONOCYTE; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; BONE DEVELOPMENT; CELL DIFFERENTIATION; HEK293 CELL LINE; MACROPHAGE; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

APOPTOSIS; CELL DIFFERENTIATION; COCULTURE TECHNIQUES; HEK293 CELLS; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; NF-KAPPA B; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; SIGNAL TRANSDUCTION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84921749669     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2350     Document Type: Article

References (41)

1. Boyce B. Advances in the regulation of osteoclasts and osteoclast functions. J Dent Res. 2013;92:860-7.
2. Yamashita T, Takahashi N, Udagawa N. New roles of osteoblasts involved in osteoclast differentiation. World J Orthop. 2012;3:175-81.
3. Broadhead M, Clark J, Dass C, Choong P, Myers D. Therapeutic targeting of osteoclast function and pathways. Expert Opin Ther Targets. 2011;15:169-81.
4. Yamanouchi D, Takei Y, Komori K. Balanced mineralization in the arterial system: possible role of osteoclastogenesis/osteoblastogenesis in abdominal aortic aneurysm and stenotic disease. Circ J. 2012;76:2732-7.
5. Itou T, Maldonado N, Yamada I, et al. Cystathionine γ-lyase accelerates osteoclast differentiation: identification of a novel regulator of osteoclastogenesis by proteomic analysis. Arterioscler Thromb Vasc Biol. 2014;34:626-34.
6. Kular J, Tickner J, Chim S, Xu J. An overview of the regulation of bone remodelling at the cellular level. Clin Biochem. 2012;45:863-73.
7. Teitelbaum S. Bone resorption by osteoclasts. Science. 2000;289:1504-8.
8. Costa-Rodrigues J, Teixeira C, Sampaio P, Fernandes M. Characterisation of the osteoclastogenic potential of human osteoblastic and fibroblastic conditioned media. J Cell Biochem. 2010;109:205-16.
9. Baum R, Gravallese E. Impact of inflammation on the osteoblast in rheumatic diseases. Curr Osteoporos Rep. 2014;12:9-16.
10. Mori G, D' Amelio P, Faccio R, Brunetti G. The interplay between the bone and the immune system. Clin Dev Immunol. 2013;2013:720504. DOI: 10.1155/2013/720504
11. Binder BR, Mihaly J, Prager GW. uPAR-uPA-PAI- 1 interactions and signaling: a vascular biologist's view. Thromb Haemost. 2007;97:336-42.
12. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002;3:932-43.
13. Pillay V, Dass C, Choong F. The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol. 2006;25:33-9.
14. Smith H, Marshall C. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol. 2010;11:23-36.
15. Shushakova N, Eden G, Dangers M, et al. The urokinase/urokinase receptor system mediates the IgG immune complex-induced inflammation in lung. J Immunol. 2005;175:4060-8.
16. Kiyan Y, Tkachuk S, Hilfiker-Kleiner D, Haller H, Fuhrman B, Dumler I. oxLDL induces inflammatory responses in vascular smooth muscle cells via urokinase receptor association with CD36 and TLR4. J Mol Cell Cardiol. 2014;66:72-82.
17. Kalbasi Anaraki P, Patecki M, Larmann J, et al. Urokinase receptor mediates osteogenic differentiation of mesenchymal stem cells and vascular calcification via the complement C5a receptor. Stem Cells Dev. 2014;23:352-62.
18. Ross F, Teitelbaum S. alphavbeta3 and macrophage colony-stimulating factor: partners in osteoclast biology. Immunol Rev. 2005;208:88-105.
19. Ma X, Liu Y, Zhang Y, Yu X, Wang W, Zhao D. Jolkinolide B inhibits RANKL-induced osteoclastogenesis by suppressing the activation [of] NF-κB and MAPK signaling pathways. Biochem Biophys Res Commun. 2014 Mar 7;445(2):282-8.
20. Mukherjee A, Rotwein P. Selective signaling by Akt1 controls osteoblast differentiation and osteoblast-mediated osteoclast development. Mol Cell Biol. 2012;32:490-500.
21. He Y, Rhodes S, Chen S, et al. c-Fms signaling mediates neurofibromatosis Type-1 osteoclast gain-in-functions. PLoS One. 2012;7:e46900.
22. May AE, Kanse SM, Lund LR, Gisler RH, Imhof BA, Preissner KT. Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. J Exp Med. 1998;188:1029-37.
23. May AE, Schmidt RE, Kanse SM, et al. Urokinase receptor surface expression regulates monocyte adhesion in acute myocardial infarction. Blood. 2002;100:3611-7.
24. Gu J-M, Johns A, Morser J, Dole WP, Greaves DR, Deng GG. Urokinase plasminogen activator receptor promotes macrophage infiltration into the vascular wall of ApoE deficient mice. J Cell Physiol. 2005;204:73-82.
25. Shushakova N, Tkachuk N, Dangers M, et al. Urokinase-induced activation of the gp130/Tyk2/Stat3 pathway mediates a pro-inflammatory effect in human mesangial cells via expression of the anaphylatoxin C5a receptor. J Cell Sci. 2005;118:2743-53.
26. Park Y, Liu G, Tsuruta Y, Lorne E, Abraham E. Participation of the urokinase receptor in neutrophil efferocytosis. Blood. 2009;114:860-70.
27. Braun T, Schett G. Pathways for bone loss in inflammatory disease. Curr Osteoporos Rep. 2012;10:101-8.
28. Massy Z, Mentaverri R, Mozar A, Brazier M, Kamel S. The pathophysiology of vascular calcification: are osteoclast-like cells the missing link? Diabetes Metab. 2008;34:S16-20.
29. Furlan F, Galbiati C, Jorgensen N, et al. Urokinase plasminogen activator receptor affects bone homeostasis by regulating osteoblast and osteoclast function. J Bone Miner Res. 2007;22:1387-96.
30. Naves M, Rodríguez-García M, Díaz-López J, Gómez-Alonso C, Cannata-Andía J. Progression of vascular calcifications is associated with greater bone loss and increased bone fractures. Osteoporosis Int. 2008;19:1161-6.
31. Simon S, Fodor D, Muntean L, Poanta L, Cristea P, Rednic S. Bone mineral density, vertebral fractures and body mass index in postmenopausal women with abdominal aortic calcification. Endocr Res. 2014;39:1-6.
32. Mody N, Parhami F, Sarafian T, Demer L. Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. Free Radic Biol Med. 2001;31:509-19.
33. Demer L, Tintut Y. The roles of lipid oxidation products and receptor activator of nuclear factor-κB signaling in atherosclerotic calcification. Circ Res. 2011;108:1482-93.
34. Rafiei S, Komarova S. Molecular signaling pathways mediating osteoclastogenesis induced by prostate cancer cells. BMC Cancer. 2013;13:605.
35. Tseng W, Graham L, Geng Y, et al. PKA- induced receptor activator of NF-kappaB ligand (RANKL) expression in vascular cells mediates osteoclastogenesis but not matrix calcification. J Biol Chem. 2010;285:29925-31.
36. Chang J, Wang Z, Tang E, et al. Inhibition of osteoblastic bone formation by nuclear factor-kappaB. Nat Med. 2009;15:682-9.
37. Yao Z, Li Y, Yin X, Dong Y, Xing L, Boyce B. NF-κB RelB negatively regulates osteoblast differentiation and bone formation. J Bone Miner Res. 2014;29:866-77.
38. Mazière C, Salle V, Gomila C, Mazière J. Oxidized low density lipoprotein increases RANKL level in human vascular cells. Involvement of oxidative stress. Biochem Biophys Res Commun. 2013;440:295-9.
39. Wang Y, Shan J, Yang W, Zheng H, Xue S. High mobility group box 1 (HMGB1) mediates high-glucose-induced calcification in vascular smooth muscle cells of saphenous veins. Inflammation. 2013;36:1592-604.
40. Hodge J, Kirkland M, Nicholson G. Multiple roles of M-CSF in human osteoclastogenesis. J Cell Biochem. 2007;102:759-68.
41. Golden L, Insogna K. The expanding role of PI3-kinase in bone. Bone. 2004;34:3-12.